Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 10326 - 10350 of 12145 in total

2G7

2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.
Investigational

(2R)-3-(phosphonooxy)propane-1,2-diyl diheptanoate

Experimental

PVX-410 component XBP1 SP367-375 (YLFPQLISV)

Investigational

(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE

Experimental
Matched Iupac: … (3aR,6R,6aS)-6-[(S)-[(1S)-cyclohex-2-en-1-yl](hydroxy)methyl]-6a-methyl-4-oxo-hexahydro-2H-furo[2,3-c …

Caroxazone

Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. However, it presents a five-fold preference for the MAO-B subtype.
Withdrawn
Matched Categories: … Heterocyclic Compounds, 1-Ring …

Pidotimod

Pidotimod is a synthetic dipeptide with immunomodulatory properties.
Experimental
Matched Categories: … Heterocyclic Compounds, 1-Ring …

Simendan

Simendan is under investigation in clinical trial NCT00527059 (Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure).
Investigational
Matched Iupac: … 1-cyano-N-[4-(6-hydroxy-4-methyl-4,5-dihydropyridazin-3-yl)phenyl]methanecarbohydrazonoyl cyanide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …

Polmacoxib

Polmacoxib has been used in trials studying the treatment of Osteoarthritis, Osteoarthritis, Hip, Osteoarthritis, Knee, Localized Primary Osteoarthritis of Hip, and Localized Primary Osteoarthritis of Knee.
Investigational
Matched Iupac: … 4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl]benzene-1-sulfonamide …
Matched Categories: … Heterocyclic Compounds, 1-Ring …

2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol

Experimental

4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide

Experimental

Guanosine 5'-diphosphate 2':3'-cyclic monophosphate

Experimental

2-deazo-6-thiophosphate guanosine-5'-monophosphate

Experimental

6-Amino-4-Hydroxymethyl-Cyclohex-4-Ene-1,2,3-Triol

Experimental

N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine

Experimental

4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID

Experimental

5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide

Experimental

(E)-(S)-4-[(S)-4-METHYL-2-((S)-3-METHYL-2{(S)-2-[(5-METHYL-ISOXAZOLE-3- CARBONYL)-AMINO]-PROPIONYLAMINO}-BUTYRYLAMINO)-PENTANOYLAMINO]-5-((S)-2- OXO-PYRROLIDIN-3-YL)-PENT-2-ENOIC ACID ETHYL ESTER

Experimental

Adenosine-5'-[Beta, Gamma-Methylene]Tetraphosphate

Experimental

5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine

Experimental

METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID

Experimental
Matched Iupac: … (2R)-N'-hydroxy-N-[(1S)-1-(methylcarbamoyl)-2-phenylethyl]-2-(2-methylpropyl)butanediamide …

TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE

Experimental

Teprasiran

Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).
Investigational

XEN-D0501

XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.
Investigational

CN-201

CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational

Arimoclomol

Arimoclomol is an experimental drug compound developed by CytRx Corporation, a biopharmaceutical company based in Los Angeles, California. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a neurodegenerative disease with no effective treatment.
Investigational
Matched Iupac: … 3-[chloro({[(2R)-2-hydroxy-3-(piperidin-1-yl)propoxy]imino})methyl]pyridin-1-ium-1-olate …
Matched Salts cas: … 289893-26-1 …
Displaying drugs 10326 - 10350 of 12145 in total